TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Stanford-led study reports that blocking the age-associated protein 15-PGDH restored knee cartilage in older mice and protected mice from arthritis after knee injury. Human cartilage samples from knee replacement surgeries also began producing new cartilage in lab tests, but the approach has not been shown to work as a treatment in people.
A Stanford-led study reports that blocking the age-associated protein 15-PGDH restored knee cartilage in older mice and helped protect mice from arthritis after knee injuries. Human cartilage samples taken during knee replacement surgeries also began producing new cartilage after treatment in laboratory tests, but the findings do not show that the approach can regrow cartilage or prevent joint replacement in people.
The researchers found that 15-PGDH levels roughly doubled in knee cartilage as mice aged. They then treated older animals with a small-molecule inhibitor of the protein. According to the study, the intervention reversed naturally occurring cartilage loss. In a separate injury experiment, it also protected mice against arthritis following knee damage designed to resemble an ACL tear in people.
The team also tested the approach on human cartilage samples collected during knee replacement surgeries. Those samples responded by beginning to produce new, functional cartilage, the report said. This is evidence of activity in human tissue outside the body—not evidence that patients treated with the drug regrew cartilage or avoided surgery.
The study, published in Science, was led by researchers at Stanford Medicine. Its senior authors were Helen Blau, a professor of microbiology and immunology, and Nidhi Bhutani, an associate professor of orthopaedic surgery. The researchers said cartilage cells already present in the tissue, called chondrocytes, changed their gene activity toward a more youthful state. The results did not point to stem cells as the source of the new cartilage.
A Potential Route to Cartilage Repair
Osteoarthritis gradually damages the cartilage that cushions joints, causing pain, swelling and difficulty moving. Current care largely manages symptoms; advanced disease can lead to joint replacement. A treatment that could slow or repair cartilage loss would address tissue damage itself, rather than only its effects, and could eventually offer another option for some patients.
That prospect remains conditional. The findings are from mice and laboratory-tested human tissue, not a clinical trial. The study offers a biological lead, but it does not establish a safe or effective medicine for people, show how much cartilage could be restored in a patient, or demonstrate that surgery could be avoided.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 7 Rechargeable Electric Toothbrush with 2 Brush Heads and Charging Travel Case
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
Why Researchers Targeted 15-PGDH
Osteoarthritis is a degenerative joint disease in which cartilage breaks down. In joints, the affected tissue is typically articular cartilage, a smooth surface that lets bones move with limited friction. It has little natural capacity to repair itself. As cartilage deteriorates, cells can produce inflammatory molecules and break down collagen, weakening the tissue further.
The Stanford team focused on 15-PGDH, a protein the researchers describe as a “gerozyme” because its levels rise with age and it is linked to declining tissue function. The protein breaks down prostaglandin E2, a molecule involved in tissue processes. The same research group had previously reported that inhibiting 15-PGDH supported regeneration in other tissues in mice, including muscle, nerve and bone. The new study tested whether that pathway also mattered in cartilage.
Osteoarthritis affects about one in five U.S. adults, according to the source report, and is associated with substantial health care costs. Those figures describe the disease burden; they do not indicate how many people might benefit from this experimental approach.
““This is a new way of regenerating adult tissue, and it has significant clinical promise for treating arthritis due to aging or injury.””
— Helen Blau, Stanford professor of microbiology and immunology and study senior author
Human Treatment Still Unproven
The findings do not establish whether 15-PGDH inhibition can safely regenerate cartilage in living people. The human-tissue tests were conducted on samples taken during surgery, while the reported repair and injury-protection results came from mice. No human treatment outcome, such as reduced pain, improved mobility or fewer joint replacements, is reported in the source material.
It is also unclear what dose, delivery method or treatment schedule might be appropriate for people, how durable any repair would be, and whether effects would differ by age, injury or disease severity. The source report discusses a possible future oral medicine or injection as a prospect, not an available or approved therapy. Claims that joint replacements are about to become unnecessary are not supported by these results.
Testing the Approach in People
The next major step would be research to establish whether the results can translate from animal models and isolated human tissue to patients. The source material does not announce a clinical trial or provide a timeline for one. Before the approach could be considered for routine care, researchers would need evidence on its safety, dosing and effectiveness in people, including whether it improves meaningful outcomes such as pain and joint function.
For now, the study is an early research finding, not a change to current osteoarthritis care. Patients should not interpret it as a reason to delay or replace medical advice about joint pain or surgery.
Key Questions
Did Stanford researchers regrow cartilage in people?
No. The study reports cartilage repair in mice and new cartilage production in human tissue samples tested in a laboratory. It does not report cartilage regrowth in patients.
What protein did the researchers block?
The team inhibited 15-PGDH, a protein whose levels rose with age in the mouse knee cartilage examined. Researchers describe it as an age-associated enzyme, or “gerozyme.”
Does this mean knee replacements will no longer be needed?
No. The findings do not show that the treatment prevents joint replacement in people. It is an experimental approach that has not been established as safe or effective in clinical care.
When could the treatment become available?
The source report gives no availability date and does not announce human trials. Further research would be needed before researchers could determine whether the approach can be developed into a treatment for patients.
Source: rss
